Top 3 ASX tech stocks to buy right now

The following three ASX tech stocks have regained momentum yet their valuations are well below previous highs and hence they offer attractive opportunities for investors looking to add high-quality growth businesses to their portfolios.

Xero Limited (ASX: XRO) 

has risen 7% at the time of writing on Wednesday as it picked up renewed momentum while current market capitalisation is $11.87 billion.
The stock is down 64% over the past 12 months but Xero has stood out as one of the best ASX tech stocks to buy right now as FY26 operating revenue was up 31% year-on-year to NZ$2.75 billion while adjusted EBITDA increased 18% to NZ$757 million.

The company expanded its customer base by 11% to 4.92 million subscribers and average revenue per customer climbed 23% to NZ$55.44 which is due to pricing power and the successful integration of Melio.

Xero also generated NZ$554 million in free cash flow and increased customer lifetime value to almost NZ$21 billion which highlights the strength of its business model.
Recent developments include the rollout of AI-powered features through JAX along with a partnership with Anthropic and continued momentum in its fastest-growing US market.

Management expects FY27 operating revenue of NZ$3.62 billion to NZ$3.73 billion and adjusted EBITDA of NZ$860 million to NZ$920 million as it is well positioned to create significant long-term value for shareholders.

Life360, Inc. (ASX: 360) 

has gained 23% over the past month as investors have started to acknowledge the company’s rapid subscriber growth and several monetisation opportunities across its family safety platform while current market capitalisation is $5.51 billion.

The stock is still down 29% in the last 12 months and Life360 is one of the best ASX technology stocks to buy today, supported by Q1 FY26 revenue growth of 38% year-on-year to US$143.1 million and a 32% increase in Annualised Monthly Revenue to US$517.9 million.

User metrics were excellent as Monthly Active Users reached 97.8 million which was up 17% year-on-year while Paying Circles rose 27% to 3.0 million and advertising revenue jumped 329% to a record US$19.7 million after the successful integration of Nativo.

The company also reported stronger financial performance as operating cash flow increased 42% to US$17.2 million and cash along with restricted cash and short-term investments grew to US$459 million which will provide substantial flexibility for future growth initiatives.

Management has upgraded FY26 guidance and now expects revenue between US$650 million and US$685 million along with Adjusted EBITDA of US$130 million to US$140 million.

Pro Medicus Limited (ASX: PME) 

has gained 38% over the past month due to renewed investor confidence in one of the most attractive ASX technology stocks despite the share price still being down 36.5% over the last 12 months while current market capitalisation is $18.52 billion.

The company in the first half of FY26 delivered record results as revenue increased 28.4% to $124.8 million while underlying EBIT rose 29.7% to $90.7 million and underlying EBIT margin reached an outstanding 72.6%.

Profit after tax climbed 230.9% to $171.2 million which highlights the strength of the business model and its ability to scale efficiently across a growing customer base.

Recent performance has been equally notable as Pro Medicus secured more than $400 million in contract value during FY26 while maintaining a strong balance sheet supported by $221.8 million in cash and investments.

The company expects a surge in transaction volumes from FY27 as major implementations including Trinity University of Colorado BayCare and other recently signed contracts become fully operational.

(Source: Company Announcements)